Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,227 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
HIV Infections
Interventions
Hepatitis B Vaccine (Recombinant), gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1991
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Nashville, Tennessee
Conditions
Kidney Transplantation, Hepatitis C
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Amit D Tevar, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Not applicable Interventional Results available

Hepatitis C-Video vs. Brochure Education Delivery

NCT04204447
Conditions
Hepatitis C
Interventions
Hepatitis C Educational Brochure, Hepatitis C Educational Video
Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Buffalo, New York • Orchard Park, New York
Completed No phase listed Observational Results available

Genetic and Biochemical Markers of Interferon-Induced Depression.

NCT00252538
Conditions
Depression
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Long Beach, California • Minneapolis, Minnesota • Portland, Oregon
Completed Phase 2 Interventional Results available

Lamivudine and Adefovir to Treat Chronic Hepatitis B

NCT00023309
Conditions
HBV (Hepatitis B Virus), Hepatitis B, Hepatitis
Interventions
Lamivudine and adefovir, Adefovir alone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hepatitis C Virus
Interventions
Placebo, Daclatasvir, Pegylated interferon alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Tulsa, Oklahoma + 1 more
Conditions
Hepatitis C, Chronic
Interventions
Sofosbuvir, RBV, PEG
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
44
States / cities
Montgomery, Alabama • Jonesboro, Arkansas • Anaheim, California + 36 more
Conditions
Hepatitis C
Interventions
Integrated care model, Usual Care Model
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 75 Years
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Palo Alto, California • San Diego, California • The Bronx, New York
Conditions
Hepatitis C
Interventions
Elbasvir/grazoprevir
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 1Phase 2 Interventional Results available

Transplanting Hepatitis C Lungs Into Negative Lung Recipients

NCT03724149
Conditions
Lung Diseases
Interventions
Zepatier, Epclusa
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 67 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Chronic Hepatitis B
Interventions
TAF, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 12 more
Conditions
Adherence
Interventions
Portal-724 MEMs Cap
Device
Lead sponsor
Saint Michael's Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Newark, New Jersey
Conditions
HIV Infections, Hepatitis C
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Stanford, California • Miami, Florida • Honolulu, Hawaii + 7 more
Completed Phase 2 Interventional Results available

Harvoni Treatment Porphyria Cutanea Tarda

NCT03118674
Conditions
Porphyria Cutanea Tarda, Hepatitis C
Interventions
Harvoni
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
San Francisco, California • Winston-Salem, North Carolina • Galveston, Texas
Conditions
Autoimmune Hepatitis, AIH
Interventions
Inebilizumab, Placebo, Standard of Care
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 74 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
6
States / cities
Little Rock, Arkansas • Northridge, California • Rialto, California + 3 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers

NCT02404805
Conditions
HIV, Hepatitis C
Interventions
dolutegravir, simeprevir
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Chronic Hepatitis C Infection in HIV Infected Persons, HIV Infections
Interventions
Peginterferon a-2a plus Ribavirin
Drug
Lead sponsor
Hepatitis Resource Network
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Conditions
Hepatitis C
Interventions
rosiglitazone
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Herpes Simplex Type 1 Suppression in Hepatitis C

NCT01580995
Conditions
Chronic Hepatitis C Infection
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Jackson, Mississippi
Conditions
Hepatitis C
Interventions
Not listed
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Hepatitis C Virus, HIV
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 31 more
Conditions
Chronic Hepatitis B
Interventions
PEGASYS
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
15
States / cities
Scottsdale, Arizona • Downey, California • Los Angeles, California + 12 more
Conditions
Hepatitis C, Chronic
Interventions
BI 201335, Pegylated Interferon-alpha (IFN), Ribavirin (RBV), Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
18
States / cities
North Little Rock, Arkansas • Englewood, Colorado • Palm Harbor, Florida + 14 more
Conditions
Chronic Hepatitis Delta
Interventions
Peginterferon Lambda
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bethesda, Maryland